Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated CareVancouver, British Columbia--(Newsfile…
Expands access to vertebrogenic pain treatment for 36 million patientsMINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company…
Program provides healthcare providers access to Diagnamed’s novel brain health AI platform Figure 1. Demonstration of CERVAI™ Brain Age™ SessionTORONTO,…
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent…
NME is a progressive, typically fatal autoimmune disease characterized by brain inflammation, that has no disease-modifying treatment options availableSAN DIEGO…
Company to Host Cancer R&D Update on October 19, 2023 to Share Latest Details of Multipronged Cancer Program Based on…
STOCKHOLM, SWEDEN / ACCESSWIRE / October 3, 2023 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical…
FORT WASHINGTON, PA / ACCESSWIRE / October 2, 2023 / CCA Industries, Inc. (OTC Pink:CAWW) has sold its Bikini Zone…
804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected…
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa…